Company news

Immix Biopharma, Inc. news in 2026

Immix Biopharma, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

October 5, 2026

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

September 30, 2026

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

September 29, 2026

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refracto...

September 29, 2026

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

August 4, 2026

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

May 22, 2026

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

May 21, 2026

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

May 21, 2026

Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)

May 7, 2026

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

April 9, 2026

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed, Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

March 31, 2026

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

March 29, 2026

Immix Biopharma to Participate in Upcoming Investor Conferences

March 3, 2026

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

January 28, 2026

Decks in 2026